<DOC>
	<DOCNO>NCT02489968</DOCNO>
	<brief_summary>Two independent study part ( i.e . Part A Part B ) include trial . Part A evaluate empagliflozin 10 mg + linagliptin Part B evaluate empagliflozin 25 mg + linagliptin . All analysis carry separately study part . The objective Part A investigate efficacy , safety tolerability fix dose combination ( FDC ) empagliflozin 10 mg / linagliptin 5 mg compare empagliflozin 10 mg plus FDC match placebo administer orally daily 24 week Japanese patient T2DM insufficient glycaemic control 16 week treatment empagliflozin 10 mg alone daily . The study design show superiority FDC empagliflozin 10 mg / linagliptin 5 mg empagliflozin 10 mg plus FDC match placebo 24 week treatment . The objective Part B investigate efficacy , safety tolerability FDC empagliflozin 25 mg / linagliptin 5 mg compare empagliflozin 25 mg plus FDC match placebo administer orally daily 24 week Japanese patient T2DM insufficient glycaemic control 16 week treatment empagliflozin 25 mg alone daily . The study design show superiority FDC empagliflozin 25 mg / linagliptin 5 mg empagliflozin 25 mg plus FDC match placebo 24 week treatment . The 24 week treatment period follow 28 week extension treatment period evaluate efficacy safety 52 week .</brief_summary>
	<brief_title>Linagliptin Add Therapy Empagliflozin 10 mg 25 mg With Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : Diagnosis type 2 diabetes prior inform consent Male female patient diet exercise regimen least 12 week prior inform consent : drugna√Øve , define antidiabetic drug least 12 week prior inform consent , pretreated one oral antidiabetic drug ( sulfonylurea , half maximum approve dose ) stable dosage least 12 week prior inform consent ( thiazolidinedione , therapy unchanged least 18 week prior inform consent ) . Individual antidiabetic drug discontinue Visit 1. haemoglobin A1c ( HbA1c ) Visit 1 ( screen ) patient without antidiabetic therapy : HbA1c &gt; =8.0 = &lt; 10.5 % patient one oral antidiabetic drug : HbA1c &gt; =7.5 = &lt; 10.5 % HbA1c &gt; =7.5 = &lt; 10.0 % Visit 4 randomisation double blind treatment period Exclusion criterion : Uncontrolled hyperglycaemia glucose level &gt; 270 mg/dL ( &gt; 15.0 mmol/L ) open label stabilisation period placebo run period Impaired renal function , define estimate glomerular filtration rate ( eGFR ) &lt; 45 mL/min/1.73m2 ( modification diet renal disease ( MDRD ) formula ) Acute coronary syndrome , stroke transient ischemic attack ( TIA ) within 12 week prior inform consent Indication liver disease , define serum level either alanine transaminase ( ALT ) , aspartate transaminase ( AST ) , alkaline phosphatase ( ALP ) 3 x upper limit normal ( ULN )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>